Fig. 2C-E), and CKS1i drug sensitivity directly correlates with CKS1B expression in poor risk AML patients (R=0.61, p=0.0078; Figure 1C), with clear separation of high and low DSS (Supp. The gene discussed is CKS1B; the disease is acute myeloid leukemia.